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a b s t r a c t
Methods that do not require animal sacrifice to detect botulinum neurotoxins (BoNTs) are critical for
BoNT antagonist discovery and the advancement of quantitative assays for biodefense and pharmaceuti-
cal applications. Here we describe the development and optimization of fluorogenic reporters that detect
the proteolytic activity of BoNT/A, B, D, E, F, and G serotypes in real time with femtomolar to picomolar
sensitivity. Notably, the reporters can detect femtomolar concentrations of BoNT/A in 4 h and BoNT/E in
20 h, sensitivity that equals that of animal-based methods. The reporters can be used to determine the
specific activity of BoNT preparations with intra- and inter-assay coefficients of variation of approxi-
mately 10%. Finally, we find that the greater sensitivity of our reporters compared with those used in
other commercially available assays makes the former attractive candidates for high-throughput screen-
ing of BoNT antagonists.
 2011 Elsevier Inc. All rights reserved.
Botulinum neurotoxins (BoNTs),1 produced by the bacteria of
the genus Clostridium, are the most lethal substances known. The
zinc-dependent endopeptidases act by entering neurons and cleav-
ing soluble N-ethylmaleimide-sensitive factor attachment protein
receptors (SNAREs) and, thus, compromise the protein machinery
responsible for neurotransmitter release [1–8]. Failure to promptly
treat a victim of BoNT poisoning can result in flaccid paralysis, respi-
ratory failure, or death [9]. The combination of extreme potency and
a lack of medical treatments other than antitoxin administration and
intensive care has made BoNT a biodefense priority requiring the
discovery and development of assays to quantify toxins and to iden-
tify antagonists to counteract intoxication [10–13].
Despite their lethality, BoNTs are widely used for cosmetic and
pharmaceutical applications due in part to their exquisite specific-
ity for the neuromuscular junction. BoNTs provide relief of muscle
tension and pain by inhibiting neurons that cause excessive muscle
contractions. Therapeutic preparations of BoNT/A and B serotypes
are Food and Drug Administration (FDA) approved for treating
glabellar lines, strabismus, cervical dystonia, blepharospasm,
cranial nerve VII disorders, and primary axillary hyperhidrosis.
Dozens of ‘‘off-label’’ BoNT clinical applications have also been
documented [14–17].
The mouse bioassay, or lethality test, has been the standard for
testing BoNT-containing samples for the past 30 years [18–20].
Government agencies use this method for testing food and serum
samples for the presence of BoNT, whereas the pharmaceutical
industry uses it for quality control and to quantify ‘‘for human
use’’ BoNT preparations. The test is carried out by injecting mice
intraperitoneally with approximately 0.5 ml of sample per mouse
and recording the number of deaths over a 1- to 7-day period.
The assay is very sensitive, with a detection limit of 5–10 pg for
BoNT/A [21,22]. Results for the mouse bioassay are reported in
median lethal dose (LD50) units, where 1 LD50 is the amount of
BoNT required to kill 50% of injected mice after a defined time
interval.
The mouse bioassay’s low-throughput methodology limits its
utility for BoNT antagonist development where small molecule li-
brary screening is impractical and could raise ethical concerns. Ra-
pid and easily accessible assays that are not dependent on animal
use are required to meet biodefense diagnostic and therapeutic
needs. Furthermore, quality control profiles of BoNT-based drugs
require reliable non-animal-based tests to measure drug-specific
activity regardless of the manufacturer. Alternative methods that
rely on immunology, liquid chromatography, mass spectrometry
(MS), and fluorescence methods to detect BoNT proteolytic activity
have emerged [23]. Notably, detection of multiple BoNT serotypes
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using a combination of immunological and MS methods has been
reported with mouse bioassay sensitivity and utility in complex
matrices such as serum and food products [24,25]. Drawbacks of
both MS and liquid chromatography methods are their limited
throughput and the requirement of expensive equipment. Fluoro-
genic methods offer a high-throughput alternative to either the
mouse bioassay or immuno-MS methods. However, most fluoro-
genic assays use low-affinity substrates, are more than four orders
of magnitude less sensitive than the mouse bioassay, and/or are
limited to only a few BoNT serotypes [26–31].
Dong and coworkers described two recombinant reporters con-
taining residues 141–206 and 33–94 of neuronal SNARE proteins
SNAP-25 and synaptobrevin 2, respectively [32]. The substrates
were expressed as fusions of cyan and yellow fluorescent proteins
(CFP and YFP, respectively), enabling the detection of BoNT prote-
olytic activity by Förster resonance energy transfer (FRET). The
fluorogenic reporters were found to be sensitive to BoNT/A, B, E,
and F serotypes and able to detect picomolar concentrations of
the toxins in real time.
Here we report advances in the development and optimization
of FRET-based reporters that detect six of seven BoNT serotypes.
Through changes in the expression, purification, and content of
the reporters, we were able to generate FRET-based reporters with
improved dynamic range and sensitivity. The resulting reporters
are robust in terms of reagent and assay stability, and they provide
sensitivity for BoNT not previously seen with fluorogenic sub-
strates. The FRET-based reporters are suitable for high-throughput
screening (HTS) for BoNT antagonists and for the development of
sensitive, real-time, and quantitative BoNT detection methods that
do not require animals.
Materials and methods
Materials and reagents
BoNT/A, B, D, and F serotypes, trypsin-treated BoNT/E, and tryp-
sin-treated BoNT/G were provided by Metabiologics (Madison, WI,
USA).
Generation and expression of FRET-based reporters
The constructs pTrcHisA–CFP–SNAP25141–206–YFP and pTrcH-
isA–CFP–Syb233–94–YFP were provided by E.R. Chapman (Univer-
sity of Wisconsin–Madison) [32]. The constructs were engineered
to encode the 8-amino-acid StrepTagII sequence (WSHPQFEK) C
terminal of the YFP moiety using standard polymerase chain reac-
tion (PCR) techniques [33]. The resulting constructs, pTrcHisA–
CFP–SNAP141–206–YFP–StrepTagII and pTrcHisA–CFP–Syb233–94–
YFP–StrepTagII, were further modified to incorporate Venus muta-
tions into YFP using standard site-directed mutagenesis and
molecular biology techniques [34]. All resulting constructs en-
coded a protein with an N-terminal His6 tag, a C-terminal StrepT-
agII, a 4-amino-acid linker (GMAS) between the His6 tag and the
donor fluorescent protein (FP), a 5-amino-acid linker (GGRSR) be-
tween the donor FP and the N terminus of SNAP25, a 6-amino-acid
linker (SNSGGS) between the C terminus of SNAP25 and the accep-
tor FP, and a 7-amino-acid linker (GIRSLAV) between the acceptor
FP and the StrepTagII.
Protein expression and purification
All FRET reporter constructs were expressed in BL21 cells
(Novagen) and purified by double affinity chromatography unless
otherwise indicated. Luria–Bertani broth (LB, 50 ml) supplemented
with 50 lg/ml carbenicillin was inoculated with a colony of BL21
cells transformed with the indicated construct and grown over-
night at 37 C with shaking (250 rpm). Then 25 ml of the overnight
culture was transferred to 1 L of LB containing 50 lg/ml carbenicil-
lin and grown to an OD600 of approximately 0.5 before induction of
protein expression by the addition of 0.4 mM isopropyl-b-D-thioga-
lactopyranoside (IPTG). The cultures were immediately transferred
to 25 C unless otherwise indicated (see Fig. 1A) and grown with
shaking for an additional 7 h. Cells were harvested by centrifuga-
tion (8000g, 10 min), washed once with 30 ml of phosphate-buf-
fered saline (PBS), and frozen at 80 C.
Thawed cell pellets from 8-L cultures were resuspended with
240 ml of B-Per Protein Extraction Reagent (Pierce) supplemented
with 500 mM NaCl, 10 mM imidazole (pH 8.0), 6 kU of benzonase
(Novagen), 240 kU of lysozyme (Novagen), and Complete Protease
Inhibitor Cocktail (Roche). The cells were extracted for 20 min on a
rotating platter at room temperature (RT) before centrifugation at
25,000g for 20 min. The supernatant was then incubated with
64 ml of nickel–nitrilotriacetic acid (Ni-NTA)–Sepharose beads
(50% slurry, Qiagen) for 45 min with rotation at RT before centri-
fuging the beads at 500g for 3 min. The beads were washed three
times with 30 ml of wash buffer (50 mM Hepes–NaOH [pH 7.1],
500 mM NaCl, and 10 mM imidazole) and transferred to a 100-ml
column. The beads were washed with an additional 3 column vol-
umes of wash buffer before elution of the protein in elution buffer
(50 mMHepes–NaOH [pH 7.1], 500 mMNaCl, and 250 mM imidaz-
ole) and the collection of 5-ml fractions.
Peak fractions were pooled and further purified by StrepTag
affinity chromatography on a Bio-Rad BioLogic fast protein liquid
chromatography (FPLC) system. His6-purified protein was injected
onto three 5-ml StrepTrap HP columns (IBA) plumbed in tandem
and equilibrated with 4 column volumes of wash buffer. Bound
protein was then washed with 4 column volumes of wash buffer
before eluting with 4–5 column volumes of 50 mM Hepes–NaOH
(pH 8.0), 150 mM NaCl, and 2.5 mM D-desthiobiotin in 1-ml fac-
tions. Peak fractions were pooled and dialyzed against 50 mM
Hepes–NaOH (pH 7.1), 10 mM NaCl, and 15% glycerol. The dialyzed
reporters were quantified by bicinchoninic acid (BCA, Pierce), ali-
quoted, and stored at 80 C.
Fluorescence measurements, BoNT assays, and analysis
Fluorescence measurements were taken on a Varioskan spectral
scanning multimode microplate reader (Thermo Scientific). Repor-
ter titrations and BoNT activity experiments were carried out in
100 ll of 50 mM Hepes–NaOH (pH 7.1), 5 mM NaCl, 0.1% Tween
20, 5 mM dithiothreitol (DTT), and 10 lM ZnCl2 in black, flat-bot-
tom, 96-well FluoroNunc plates (Nunc) unless otherwise indicated.
The reporter concentrations were maintained at 250 nM unless
otherwise indicated.
Data analysis was carried out with Prism 4.0 software (Graph-
Pad Software). For all line graphs, data shown are averages from
triplicate determinations with bars indicating standard deviations.
Raw spectral scanning data and electropherogram images are rep-
resentative data from at least three experiments. Limits of detec-
tion (LODs) were calculated by determining the minimal BoNT
concentration producing a signal more than 3 standard deviations
below control values in the absence of BoNT (n = 6).
Kinetics
The Michaelis constant (KM) and catalytic constant (kcat) were
determined by titrating a fixed concentration of the indicated BoNT
serotype (62 nM, reduced with 5 mM DTT, 30 min) with 0.2–
50 lM of the indicated substrate (FRET reporter). Emission from
470 and 527 nm on 434 nm excitation was collected every 30–
60 s for at least 20 min. On completion of the kinetic reading,
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remaining substrate was allowed to digest overnight following the
addition of excess BoNT (10 nm, BoNTs/A and E) or 100 lg/ml tryp-
sin for 30 min (BoNTs/B, D, and F). Emission spectra were deter-
mined from the completely digested substrate.
Substrate disappearance was calculated at each time point and
for a particular substrate concentration using the equation (X –
neg)/(pos – neg), where X is the emission value (527/470) at a gi-
ven time point, neg is the value in the absence of BoNT, and pos
is the value on the complete conversion of substrate into product.
Substrate disappearance at each substrate concentration was plot-
ted as a function of time, and the linear range of substrate disap-
pearance (<20% conversion) was fitted by linear regression. The
slopes of the line or velocities (v) were then plotted as a function
of substrate concentration ([S]), and the data were fitted by the
Michaelis–Menten equation, v = (Vmax  [S])/(Km + [S]), using Prism
software.
Results
Expression and purification of FRET reporters
The recombinant FRET reporters described by Dong and
coworkers are composed of CFP and YFP connected by linkers con-
taining residues 141–206 of SNAP-25 and 33–94 of synaptobrevin
2 [32]. The recombinant reporters have been named BoTest™ along
with the designation of A/E (BoTest™ A/E, CFP–SNAP–25141–206–
YFP) or B/D/F/G (BoTest™ B/D/F/G, CFP–Synaptobrevin233–94–YFP)
based on the specificity of their respective substrates for the differ-
ent BoNT serotypes as described below. The CFP and YFP moieties
form a FRET pair where, in the intact reporter, CFP excitation leads
to YFP excitation by FRET, thereby quenching the fluorescence
emission from CFP while increasing the fluorescence emission
from YFP. Treating the reporter with BoNT leads to linker cleavage
and loss of FRET, thereby decreasing YFP emission and increasing
CFP emission. Cleavage of the reporters can be followed in real
time by measuring the ratio of YFP to CFP emission.
On initial characterization, we found that the BoTest™ reporters
as previously described suffered from low yields and low purity on
expression and purification. In addition, the dynamic range of the
assay was limited by small changes in FRET fluorescence on cleav-
age of the reporters by BoNT [32]. We addressed these problems by
examining the bacterial expression conditions for producing the
reporters and modifying the constructs to include alternative fluo-
rophores and additional affinity purification tags (Fig. 1). Reducing
the reporter bacterial expression temperature to 25 C from 37 C
resulted in a dramatic increase in FRET fluorescence as judged by
an increase in fluorescence emission at 526 nm, the fluorescence
emission maximum for YFP (Fig. 1A). In addition, the drop in
expression temperature improved lot-to-lot reporter consistency
(data not shown). The increased FRET fluorescence on reducing
the expression temperature likely reflects the poor folding and
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Fig.1. Optimization of BoTest™ reporters. (A) Optimization of bacterial expression temperature. The BoTest™ A/E reporter was expressed on IPTG induction, as described in
Materials and Methods, at 37 C (solid line) or 25 C (dashed line) and purified by Ni-NTA affinity chromatography. The reporter (1 lM) was then excited at 434 nm, and the
emission spectra were collected from 450 to 550 nm. (B) Schematic of BoTest™ reporter constructs. The reporter constructs were expressed with an N-terminal His6 tag and a
C-terminal StrepTagII (ST) tag. syb, synaptobrevin 2. (C) More than 90% purification of BoTest™ reporters. The BoTest™ A/E reporter was expressed and purified as described in
Materials and Methods. Sample purity was analyzed using an Experion Automated Electrophoresis System (Bio-Rad) according to the manufacturer’s directions. The
chromatograms show separations of the Ni-NTA affinity-purified reporter (left) and the Ni-NTA StrepTagII double affinity-purified reporter (right). Internal standards and
systems are indicated () and should not be taken into account when assessing purity. Insets show fluorescence emission scans (Ex434nm/Em450–500nm) of the Ni-NTA affinity-
or double affinity-purified reporters. (D) Replacement of YFP with Venus reduces the salt sensitivity of the BoTest™ reporters. BoTest™ A/E reporters containing YFP (left) and
Venus (right) moieties were expressed and double affinity purified. The reporters (1 lM) were incubated with the indicated NaCl concentrations, and fluorescence emissions
were collected as described in panel A. For all emission scans, the CFP and FRET peaks are denoted by open and closed arrowheads, respectively.
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maturation characteristics of YFP at 37 C [34]. Thus, the lowered
expression temperatures increased the proportion of reporter mol-
ecules that have functional fluorescent proteins.
The full-length BoTest™ reporters copurified with lower molec-
ular weight proteins on subjecting the protein extracts to Ni-NTA
affinity chromatography, limiting the purity of the reporters to
60–70% (Fig. 1C). In an effort to eliminate these low-molecular-
weight proteins, we tested increasing the stringency of the affinity
purification, alternative bacterial expression cell lines, and a C-ter-
minal His-tag version of the reporter, all to no avail (data not
shown). Therefore, we incorporated a second affinity tag to allow
double affinity purification of the reporters, adding a StrepTagII
affinity tag to the C terminus of the reporter (Fig. 1B) [33]. The
reporters were first purified by Ni-NTA affinity chromatography
via the N-terminal His6 tag and then subjected to StrepTactin affin-
ity chromatography, yielding high-purity BoTest™ reporters
(Fig. 1C). The BoTest™ A/E and BoTest™ B/D/F/G reporters are
now routinely purified to greater than 90% homogeneity. The dou-
ble affinity purification scheme also increased the ratio of FRET
fluorescence to CFP fluorescence, indicating that some of the lower
molecular weight proteins were composed of truncated products
containing fluorescent CFP but no or truncated YFP (Fig. 1C, insets).
The final change to the reporters was the replacement of YFP
with the YFP derivative Venus. Venus differs from YFP by 5 amino
acid mutations that improve protein folding characteristics and re-
duce fluorescence quenching by halide anions [34]. We found that
replacement of YFP with Venus reduced the reporter’s NaCl sensi-
tivity, increasing the FRET emission of the reporters in the presence
of salt-containing buffers (Fig. 1D). The cumulative effects of the
expression, purification, and fluorophore changes resulted in
high-purity reporters with greatly improved FRET emission com-
pared with the original reporters.
Reporter fluorescence performance, signal linearity, and stability
The improved fluorescence properties of the reporters increased
assay dynamic range. BoNT proteolytic activity produced a dramatic
decrease in FRET fluorescence emission and a concurrent increase
in CFP emission (Fig. 2A). The ratio of FRET fluorescence to CFP
fluorescence dropped from approximately 2.5 in the absence of
BoNT to 0.6 in the presence of BoNT/A for the BoTest™ A/E reporter.
For the BoTest™ B/D/F/G reporter, the ratio dropped from approxi-
mately 3.6 in the absence of BoNT to 0.6 in the presence of BoNT/B.
The previous iteration of the reporters had a ratiometric (FRET
emission/CFP emission) value of approximately 0.75 in the absence
of BoNT and 0.55 in the presence of BoNT [32]. Thus, assay dynamic
range was improved approximately 10- to 15-fold on implementa-
tion of the changes described above.
BoNT reporters containing a single CFP moiety and single or
multiple YFP moieties were previously shown to exhibit nonlinear
fluorescence emission characteristics on reporter dilution [29]. The
ratio of FRET fluorescence emission to CFP fluorescence increased
with increasing reporter concentrations, indicating that FRET
efficiency was concentration dependent. This effect may be due
to reporter dimerization at high nanomolar to micromolar concen-
trations where intermolecular FRET, in addition to concentration-
independent intramolecular FRET, contributes to the overall FRET
fluorescence emission. Indeed, some green fluorescent protein
(GFP) derivatives exhibit concentration-dependent dimerization
[35,36]. These nonlinear effects have consequences for assay preci-
sion because errors in reporter dilution can lead to changes in the
ratiometric value of the assay, thereby reducing accuracy. In addi-
tion, the change in ratiometric value in response to BoNT cleavage
or the interactions between BoNT and the reporter substrate may
be influenced by intermolecular reporter dimerization. Therefore,
we tested whether the BoTest™ reporters exhibited nonlinear con-
centration-dependent changes in fluorescence emission.
We found that both the FRET and CFP fluorescence emissions
increased in a linear fashion with increased BoTest™ A/E reporter
concentrations of up to 8 lM (Fig. 2B). The linear increases were
independent of whether or not the reporter was cleaved with
BoNT. Between 8 and 16 lM, there was a small nonlinearity in
both FRET and CFP emissions, likely due to inner filter effects; no
evidence of intermolecular FRET was seen [37]. Finally, reporter
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Fig.2. The BoTest™ reporters’ fluorescence response is linear over a wide range of reporter concentrations. (A) Fluorescence emissions of BoTest™ reporters in response to
BoNT proteolytic activity. The BoTest™ A/E (left) and BoTest™ B/D/F/G (right) reporters were incubated with the indicated concentrations of BoNTs/A and B, respectively, for
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ratiometric values were concentration independent in the presence
and absence of BoNT, indicating that FRET efficiency is solely
dependent on the intramolecular interactions of the CFP and YFP
moieties (Fig. 2C). These data indicate that reporter fluorescence
performance will not be subject to errors in reporter dilution. Sim-
ilar results were seen with the BoTest™ B/D/F/G reporter (data not
shown).
The stability of BoTest™ reporters’ fluorescence characteristics
and BoNT sensitivity was examined in response to prolonged stor-
age at elevated temperatures and to freeze–thaw cycling (see Sup-
plementary material). The reporters were found to be stable on
storage at RT (or 37 C) for up to 7 days, as indicated by an absence
of loss in fluorescence emission or BoNT sensitivity (see Suppl.
Fig. 1 in supplementary material). In addition, the reporters could
be freeze–thawed 10 times without loss in performance (Suppl.
Fig. 2). The data indicate that reporter CFP and Venus moieties
do not denature under the conditions examined and that the
reporters are stable and robust.
Sensitivity of BoTest™ reporters, time, and temperature dependence
The BoTest™ A/E reporter has the potential to detect the prote-
olytic activity of BoNTs/A, C, and E, whereas the BoTest™ B/D/F/G
reporter has the potential to detect the proteolytic activity of BoN-
Ts/B, D, F, and G. We found that the BoTest™ A/E reporter was sen-
sitive to BoNT/A holotoxin and trypsinized (nicked) BoNT/E (BoNT/
Etryp) holotoxin with detection of less than 10 pM of each toxin
possible within 1 h (Fig. 3). The sensitivity of the BoTest™ A/E re-
porter to BoNT/A was both time and temperature dependent
(Fig. 3, upper panels). At 37 C, the reaction was largely complete
after 1 h, with very little additional cleavage seen even after 4 h.
At 25 or 30 C, BoNT/A continued to cleave reporter for up to
20 h, with 300 fM toxin being detectable at both temperatures.
The temperature dependency of BoNT/A cleavage of the BoTest™
A/E reporter likely reflects the thermal stability of BoNT/A rather
than the stability of the reporter given that incubation of the repor-
ter at 37 C for up to 7 days does not affect the sensitivity of the re-
porter to BoNT/A (Suppl. Fig. 1). BoTest™ A/E reporter sensitivity to
BoNT/Etryp was time dependent but unaffected by temperature
variation between 25 and 37 C (Fig. 3, lower panels). BoNT/Etryp
continued to cleave the reporter for up to 20 h at all temperatures
tested. BoNT/C holotoxin (up to 10 nm) did not cleave the BoTest™
A/E reporter (data not shown).
The BoTest™ B/D/F/G reporter detected the proteolytic activity
of BoNT/B, D, and F holotoxin and trypsin-treated BoNT/G with
varying sensitivities (Fig. 4). Picomolar quantities of BoNTs/B, D,
and F were detectable within 1–2 h of incubation at 37 C, whereas
detection of picomolar quantities of BoNT/G required overnight
incubation.
Table 1 summarizes the LODs for the six detectable serotypes of
BoNT. Less than 30 pM of the six serotypes could be detected with-
in a 20-h incubation, although the LODs varied considerably among
the serotypes. In addition, we found that LODs were dependent on
the lot of BoNTs tested and the degree of ‘‘nicking’’ that the BoNTs
undergo during expression. For example, the LODs for two lots of
BoNT/A varied 3- to 10-fold depending on the incubation temper-
ature and time (Table 1). In addition, detection of BoNT/B could be
enhanced 3-fold by trypsin treatment of the toxin. Exogenous pro-
teolytic nicking of certain clostridial toxins, notably serotypes B, D,
E, and F, is required to generate the fully active dichain form of
BoNT given that these toxins are only partially activated by endog-
enous proteases during bacterial expression [38–40]. These data
indicate that the BoTest™ LODs will be greatly affected by the
‘‘nicked’’ status of the BoNT preparations.
One mouse LD50 is estimated to be 4–20 pg of BoNT per injec-
tion depending on the serotype under consideration and the toxic-
ity of the particular preparation of BoNT [21,22]. BoNTs/A and E
(300 fM) could be detected under optimal conditions, correspond-
ing to approximately 4.5 pg of BoNT in the 100-ll reaction volume.
Thus, the mouse bioassay level of detection of BoNTs/A and E is
possible with the BoTest™ A/E reporter. BoNTs/Btryp and F (3 pM
or 45 pg) were detectable on extended 20-h incubations with
the BoTest™ B/D/F/G reporter, whereas more than 30 pM or
450 pg of BoNTs/D and G was detectable. Thus, the BoTest™ report-
ers are able to detect two serotypes (A and E) with mouse bioassay
sensitivity, two serotypes (B and F) within an order of magnitude of
bioassay sensitivity, and two serotypes (D and G) within two or-
ders of magnitude of bioassay sensitivity.
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Real-time detection of substrate disappearance
A potential advantage of using a ratiometric fluorescence read-
out to detect BoNT-dependent BoTest™ reporter cleavage is the
ability to directly correlate changes in the ratiometric value to
changes in substrate (intact reporter) concentration. Therefore,
we tested whether changes in the ratiometric fluorescence value
on the addition of increasing BoNT/A concentrations yielded corre-
sponding and proportional changes in intact BoTest™ reporter
(substrate) concentrations (Fig. 5). The BoTest™ A/E reporter was
titrated with BoNT/A, and the ratiometric value was determined
(Fig. 5A) immediately before adding sodium dodecyl sulfate
(SDS) buffer and analyzing the reaction for the presence of intact
BoTest™ reporter and cleavage products by automated electropho-
resis (Fig. 5B). Intact reporter was clearly resolved from cleavage
products in electropherograms. Overlaying normalized ratiometric
values with the percentage intact reporter as a function of BoNT/A
concentration indicated that changes in the ratiometric fluorescence
values were closely correlated with remaining intact reporter con-
centration (Fig. 5C). Finally, the normalized ratiometric values from
three independent runs were plotted against the amounts of intact
reporter remaining from the runs as determined by automated
electrophoresis (Fig. 5D). The data fit demonstrates that the ratio-
metric value is highly dependent on the amount of remaining in-
tact BoTest™ reporter, with a slope approaching unity
(0.97 ± 0.02, r2 = 0.99). Thus, substrate concentration can be fol-
lowed in real time so long as the starting ratiometric value before
the addition of BoNT and the saturated ratiometric value in the
presence of excess BoNT are known.
The ability to easily determine the BoTest™ reporter (substrate)
concentration in real time allows the rapid and potentially accu-
rate assessment of specific enzymatic activity from a given BoNT
preparation. We titrated the BoTest™ A/E reporter with BoNT/A
and measured the ratiometric fluorescence value of the reporter
every 30 s to determined the BoNT/A preparation’s specific activity
(Fig. 6). The raw ratiometric fluorescence values were normalized
and converted to substrate concentration (Fig. 6A). The initial
velocity of reaction at varying BoNT/A concentrations was then
determined by linear regression of the data points between 1
and 10 min (Fig. 6B). The initial velocity was then plotted as a func-
tion of BoNT/A concentration (Fig. 6C). The linear range of the plot
was fitted again by regression, and specific activity was deter-
mined (in nM substrate cleaved min1 nM BoNT/A1). Finally, the
BoNT/A preparation’s specific activity was determined indepen-
dently in three successive runs, with each experiment using inde-
pendently diluted BoNT/A and reagents (Fig. 6D). The data show
that a BoNT/A preparation’s specific activity can be determined
with an intraassay coefficient of variation (CV) of 9.0–10.5% and
an interassay CV of 9.5%. This is considerably more accurate than
the mouse bioassay, where CVs are typically on the order of 20–
40% depending on the methods and the number of mice used, with
the more accurate bioassay methods requiring more than 100 mice
for a single determination [20,41].
BoTest™ kinetic parameters
We determined the relative affinities and catalytic efficiencies
of BoTest™ reporter cleavage by BoNT (Table 2). The Michaelis
constant (KM) values for BoTest™ A/E cleavage by BoNT/A and E
holotoxin were determined to be less than 1 lM, likely reflecting
the extensive BoNT/A and E binding elements contained within
the reporter [6,42]. Comparisons between kinetic parameters
determined by multiple laboratories are difficult due to difference
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20 h, the reporter was excited at 434 nm, and the emission was collected at 470 and
526 nm. The emission ratio (526/470) was plotted as a function of BoNT
concentration.
Table 1
Limits of detection for the BoTest™ reporters.
Temperature (C) Time (h) BoTest™ A/E BoTest™ B/D/F/G
BoNT/A BoNT/Etryp BoNT/B BoNT/Btryp BoNT/D BoNT/F BoNT/Gtryp
lot 1 lot 2
25 1 10 30 3 1000 100 1000 100 >10000
2 3 10 3 100 100 1000 100 10000
4 3 3 1 100 30 300 30 1000
20 0.3 0.3 1 10 3 100 3 30
30 1 3 10 3 100 100 1000 100 >10000
2 1 10 3 30 10 300 100 300
4 0.3 3 1 30 10 300 30 300
20 0.3 0.3 0.3 10 3 100 3 30
37 1 3 10 3 100 30 1000 100 >10000
2 3 10 3 30 10 300 30 300
4 3 10 1 30 10 300 30 300
20 ND 3 1 10 3 30 10 30
Note: Values are in picomolars (pM) BoNT. ND, not determined.
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in the substrates, BoNT forms (e.g., light chain vs. holotoxin),
assays, and reaction conditions used. However, the KM values for
recombinant light chain cleavage of recombinant SNAP-25 were
previously determined to be 10–41 lM and 5–8 lM for BoNTs/A
and E, respectively [43–46]. The KM values determined for cleavage
of BoTest™ A/E are one order of magnitude lower, but again com-
parisons are limited by differences in assay parameters. Previous
determinations were carried out using an endpoint gel shift assay,
whereas we used a real-time kinetic approach. Regardless, these
results suggest that the BoTest™ A/E reporter binds to BoNTs/A
and E with high affinity and is efficiently cleaved by the respective
proteases.
The KM values for the cleavage of BoTest™ B/D/F/G by BoNTs/B,
D, and F range from 8.5 to 17.5 lM. Similar values were reported
for cleavage of recombinant synaptobrevin (residues 1–96 or 1–
97) by the three serotypes using gel shift assays [47,48]. The KM
values for cleavage of BoTest™ B/D/F/G are more than 10 times
higher than the KM values for cleavage of BoTest™ A/E by BoNTs/
A and E. In addition, the catalytic efficiencies (kcat/KM) for BoNTs/
B, D, and F are one to three orders of magnitude lower than those
for BoNTs/A and E. Overall, the cleavage of BoTest™ B/D/F/G repor-
ter occurs with lower affinity and efficiency than the cleavage of
BoTest™ A/E reporter.
Comparisons with SNAPtide
BoNT antagonist development, and thus the development of
therapies, is hampered by the lack of high-throughput assays that
can replicate native BoNT–substrate interactions and can be used
in a cost-effective manner. SNAPtide (List Biological Laboratories)
is a fluorogenic reporter for the detection of BoNT/A proteolytic
activity that has long been used to characterize BoNT–drug interac-
tions or BoNT enzymatic activity [49–52]. This reporter consists of
a short peptide sequence with an internal donor/acceptor FRET
pair, with the acceptor acting as a quencher. Cleavage of the pep-
tide results in an increase of fluorescence emission due to loss of
donor quenching. The relatively short peptide sequence used in
SNAPtide, however, results in a substrate that must be used at high
concentrations due to its low affinity for BoNT.
To determine whether BoTest™ provides a better alternative for
high-throughput applications, we compared SNAPtide and BoTest™
for their ability to detect BoNT/A proteolytic activity with statisti-
cal significance (Fig. 7). BoTest™, as expected, could detect picom-
olar concentrations of BoNT/A, whereas SNAPtide provided little
detection below 1 nM BoNT (Fig. 7A). We next analyzed the data
for statistical significance using Z0 factor calculations to assess as-
say dynamic range and data variation, with a Z0 factor value of
more than 0.5 signifying an acceptable assay for high-throughput
applications [53]. The BoTest™ assay gave Z0 factor values of more
than 0.5 at BoNT/A concentrations of 10 pM or above, whereas the
SNAPtide assay gave acceptable values at BoNT/A concentrations of
3 nM or above (Fig. 7B). The 300-fold difference in BoNT/A concen-
trations required to meet a common acceptance criterion for HTS
between BoTest™ and SNAPtide has implications for the cost of car-
rying out large-scale drug screening projects. The commercial
BoNT/A cost for a single 96-well plate is approximately US $0.07
at 10 pM and $21.62 at 3 nM; thus, for SNAPtide the cost of the en-
zyme (BoNT) will be one of the major considerations for HTS appli-
cations, whereas for BoTest™ the cost of enzyme will be of minimal
consideration.
Discussion
BoTest™ reporters have several advantages over existing BoNT
detection platforms. The reporters do not require animal sacrifice,
offer real-time capabilities, and do not require sophisticated equip-
ment or extensive training to perform. They also offer a single
methodology for the detection of six of seven serotypes of BoNT,
the only technology to do so outside of MS- and high-performance
liquid chromatography (HPLC)-based platforms. Efforts to adapt
the reporters for BoNT/C, the only serotype not detected by these
reporters, are ongoing. Finally, these reporters are high-affinity
BoNT substrates that offer picomolar to femtomolar sensitivity
depending on the serotypes of interest.
BoNT antagonist development has been largely limited to stud-
ies of small sets of compounds or peptides chosen through rational
design, computer-assisted, or other methods [54–59]. Although
these studies have provided a considerable amount of information
about BoNT catalytic mechanism and substrate requirements, few
of the small molecule inhibitors that have emerged from these
studies have sufficient potency to be effective BoNT therapeutics.
Large-scale HTS efforts, the basis for most modern drug discovery,
are absent from BoNT antagonist development programs; thus, the
potential of the many small molecule and natural product libraries
found at public and private laboratories has been largely untapped.
Successful development of BoNT therapeutics could be accelerated
greatly if screens of more than 10,000 compounds were more com-
monplace and the information from those screens was shared
among biodefense laboratories.
A partial explanation for the lack of large-scale HTS efforts likely
resides in the lack of assays suitable for HTS. A variety of novel
BoNT detection platforms with varying sensitivities, serotype spec-
ificities, and mechanisms have been described [23]. However, few
platforms are suitable for HTS because many require multiple
detection steps to complete, lack sensitivity, or require equipment
that is too expensive or ill-suited for HTS applications. For exam-
ple, many fluorescent-based methods for the detection of BoNT/A
that rely on synthetic peptides often use short substrates with
low affinity and low sensitivity [27,28,52]. The poor sensitivity re-
quires that large quantities of BoNT be used to generate a suitable
signal, raising the cost of HTS to unacceptable levels (Fig. 7). Fur-
thermore, the low-affinity substrates limit the number and types
of inhibitors obtained from the screens. Ideally, HTS is carried
out with a substrate concentration at or near the KM value of the
enzyme to be screened to increase inhibitor mechanism diversity
[60]. Many fluorescence-based reporters have reported KM values
of 100 lM or above; thus, high concentrations of reporter must
be used, further increasing the costs of HTS [28,52]. Short sub-
strates also limit screens to active site inhibitors while ignoring
the potential of exploiting the strong binding interactions or
exosites that occur between BoNT and longer substrates, such as
the BoTest™ reporters, that are remote from the active site
[6,7,44,47,48,61–63].
Table 2
Kinetic constants of BoTest™ reporter cleavage by BoNT.
BoTest™ A/E BoTest™ B/D/F/G
BoNT/A BoNT/Etryp BoNT/B BoNT/D BoNT/F
KM (lM) 0.67 ± 0.06 0.45 ± 0.16 15.9 ± 2.4 17.5 ± 2.0 8.50 ± 1.7
kCat (s1) 4.16 ± 0.28 14.6 ± 1.1 1.43 ± 0.72 0.30 ± 0.02 4.38 ± 0.53
kCat/KM (lM1 s1) 6.18 ± 0.20 36.3 ± 16 0.11 ± 0.05 0.017 ± 0.002 0.58 ± 0.9
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The detection methods described here meet the requirements
for HTS. First, the BoTest™ assays require only a single mix and read
step. Second, the BoTest™ assays are sensitive and meet common
criteria for acceptable HTS assay performance (Table 1 and
Fig. 7). Third, the reporters used in the assays react with BoNT with
low or sub-micromolar KM values, allowing cost-effective drug
testing using substrate concentrations at or near the KM value of
the reaction. Future studies done by our group or by laboratories
using the BoTest™ assays will fully realize the potential of the
reporters for BoNT inhibitor discovery.
A second area of advancements represented by these methods
is the ability to accurately quantify BoNT proteolytic activity from
six of seven serotypes with high sensitivity, relative ease, and
application-specific adaptability. The assays can be used in an end-
point fashion with femtomolar to picomolar sensitivity (Figs. 3 and
4), or they can be used to quantify enzyme-specific activity with
CVs of approximately 10% (Fig. 6). Ongoing work also shows that
the assays can be used in combination with immunological meth-
ods to measure the activity in complex matrices such as serum,
carrot juice, and whole blood (data not shown). With further adap-
tation, the BoTest™ assays should be applicable to a wide range of
environmental, biodefense, drug manufacturing, and pharmaceuti-
cal needs where high sensitivity detection of BoNT activity is
required.
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